Clinical trials: Safety Study
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05069129
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08), Inactivated COVID-19 vaccine (Vero cells), 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- Where
- United Arab Emirates
- Volunteers
- 1,848 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Malaria
Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers
Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. This is a phase I evaluation to assess the safety and pharmacokinetic profile of this drug in healthy adult…
- Trial name
- NCT00791531
- Testing
- Methotrexate
- Where
- Kenya
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Hepatic Impairment
Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.
To characterize the pharmacokinetics and safety of alpelisib in subjects with hepatic impairment compared to matched healthy control subjects.
- Trial name
- NCT02624557
- Testing
- Alpelisib
- Where
- 4 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Study of Oral YUQ-A1007 in Healthy Volunteers
YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD. YUQ-A1007 has not been evaluated in human clinical studies.
- Trial name
- NCT06835296
- Testing
- YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Discoid Lupus Erythematosus
Topical Nicotinamide in Treatment of DLE
Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin.
- Trial name
- NCT05362188
- Testing
- Nicotinamide Topical
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Nonobstructive Hypertrophic Cardiomyopathy
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
- Trial name
- NCT07867288
- Testing
- HTX-001
- Where
- 3 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Haya Therapeutics, Inc.
Cognitive Function
Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Cognitive Function
This study was the evaluate the efficacy and safety of hydrolysed red ginseng extract on the improvement of Cognitive Function
- Trial name
- NCT04184388
- Testing
- Hydrolysed Red Ginseng Extract
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Healthy
Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses
To determine the safety, tolerability, and drug absorption profile of multiple IV doses of BLI 489 in healthy subjects.
- Trial name
- NCT00909688
- Testing
- BLI-489
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Orthopoxviral Disease
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers.
- Trial name
- 246-Safety (NCT00907803)
- Testing
- ST-246 400 mg, ST-246 600 mg
- Where
- 3 sites in United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
Progesterone, Contraceptive Methods
Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
The aim of this study is to assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level
- Trial name
- NCT05742503
- Testing
- Depo-Provera, Implanon, Norgestrel
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tanta University
Chin Augmentation
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
- Trial name
- NCT07566286
- Testing
- Restylane Lyft with Lidocaine
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Healthy Volunteers, Safety
Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.
The goal of this clinical trial is to evaluate the safety and tolerability of RCS-21 in healthy volunteers. Participants will be asked to inhale a single dose or multiple doses of RCS-21 and their health status will be constantly…
- Conditions
- Healthy Volunteers, Safety, Tolerability, Pharmacokinetics
- Trial name
- AMIR-21 (NCT06752122)
- Testing
- RCS-21 (SAD), RCS-21 (MD)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- RNATICS GmbH
Aging
Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging
Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.
- Trial name
- NCT04946383
- Testing
- Dasatinib plus Quercetin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Drug Interaction, GERD (Gastroesophageal Reflux Disease)
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
This is an open, single arm, single-center Phase I trial designed to evaluate the effect of seven days repeated oral doses of linaprazan glurate on the pharmacokinetics (PK) of repeated doses of amoxicillin in healthy male and…
- Conditions
- Drug Interaction, GERD (Gastroesophageal Reflux Disease), Safety, and Tolerability
- Trial name
- NCT07308041
- Testing
- Drug Drug Interaction
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Hypercholesterolemia
Safety Study of Bile Acid to Treat Hypercholesteremia
Preclinical data support the hypothesis that the administration of AHRO-001 reduces LDL cholesterol levels, improves HDL function, and finally, decreases atheromatous plaque burden.
- Trial name
- NCT01931241
- Testing
- AHRO-001
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AtheroNova Inc.
Escherichia Coli Diarrhea
Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
The purpose of this study is to determine if the ETEC vaccine ETVAX with and without dmLT adjuvant is safe and immunogenic in adults, children, toddlers and infants in Bangladesh.
- Trial name
- ETVAX/dmLT (NCT02531802)
- Testing
- ETVAX, dmLT, Bicarbonate Buffer
- Where
- Bangladesh
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- PATH
Tinea Pedis
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and…
- Trial name
- NCT03999437
- Testing
- TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control
- Where
- Philippines
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- United Laboratories
Healthy, Safety Issues
Effect of an Polyphenolic Beverage in Healthy Volunteers
Currently, there are different strategies to prevent the effect of beverages and foods on blood glucose levels after ingestion. In this sense, polyphenols are a promising field; these compounds are secondary metabolites produced…
- Trial name
- PB (NCT05802472)
- Testing
- Polyphenolic beverage from extract of Vachellia farnesiana
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Healthy Volunteers
A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers
This study is designed to evaluate the safety and tolerability of UCB7858 when given as single ascending doses administered by intravenous or subcutaneous infusion in healthy subjects.
- Trial name
- NCT02879877
- Testing
- UCB7858
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.